<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04151212</url>
  </required_header>
  <id_info>
    <org_study_id>BAT5906-001-CR</org_study_id>
    <nct_id>NCT04151212</nct_id>
  </id_info>
  <brief_title>A Phase I Clinical Trial of BAT5906 Injection in Patients With Wet Age-related Macular Degeneration</brief_title>
  <official_title>A Phase I Clinical Trial for BAT5906(Single-dose;for Injection) on Safety and Pharmacokinetics for Patients With Age-related Macular Degeneration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bio-Thera Solutions</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bio-Thera Solutions</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase I Clinical Trial for BAT5906(single-dose;for injection) on Safety and
      Pharmacokinetics for Patients with Age-related macular degeneration.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective: To evaluate the safety and Pharmacokinetics of BAT5906 (single-dose
      Ophthalmic Intracireal Iinjection) in patients wAMD , when the injection dosage escalates.

      The Secondary objective: To evaluate the immunogenicity profile of BAT5906; To evaluate the
      pharmacodynamics and therapeutic efficacy profile of BAT5906.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 30, 2018</start_date>
  <completion_date type="Anticipated">June 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose-limiting toxicity(DLT)</measure>
    <time_frame>2 weeks</time_frame>
    <description>Safety and tolerability endpoint</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum tolerated dosed(MTD)</measure>
    <time_frame>0-70days</time_frame>
    <description>Safety and tolerability endpoint</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the curve(AUC0-t, AUC0-inf)</measure>
    <time_frame>0-70days</time_frame>
    <description>Pharmacokinetic endpoint Pharmacokinetic endpoint</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum serum drug concentration(Cmax)</measure>
    <time_frame>0-70days</time_frame>
    <description>Pharmacokinetic endpoint Pharmacokinetic endpoint</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Half-life period(t1/2)</measure>
    <time_frame>0-70days</time_frame>
    <description>Pharmacokinetic endpoint</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum serum drug time(Tmax)</measure>
    <time_frame>0-70days</time_frame>
    <description>Pharmacokinetic endpoint</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma clearance(CL)</measure>
    <time_frame>0-70days</time_frame>
    <description>Pharmacokinetic endpoint</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Anti-drug antibodies(ADA)</measure>
    <time_frame>0-70days</time_frame>
    <description>Immunogenic endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best correct vision(BCVA)</measure>
    <time_frame>0-70days</time_frame>
    <description>Effective endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Central Retinal thickness(CRT)</measure>
    <time_frame>0-70days</time_frame>
    <description>Effective endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VEGF concentration</measure>
    <time_frame>0-70days</time_frame>
    <description>Pharmacodynamics endpoint</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">39</enrollment>
  <condition>Age-related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>BAT5906 injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose escalation starting from 0.3mg. Route of administration: intravitreal injection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BAT5906 injection</intervention_name>
    <description>Signal dose escalation starting from 0.3mg. Route of administration: intravitreal injection</description>
    <arm_group_label>BAT5906 injection</arm_group_label>
    <other_name>No Other Intervention Names</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female aged 50-80 years old .

          -  Signing the informed consent form and able and willing to comply with all treatment
             and follow-up study procedures.

          -  The study eye must meet all the following inclusion criteria: To be diagnosed as wet
             age related macular degeneration, and there are still active lesions currently;Total
             lesion size of ≤30mm2( 12 disc areas);Best corrected visual acuity ≤70 Early Treatment
             of Diabetic Retinopathy ;Study letters (≤20/40) in the study eye.

          -  Best corrected visual acuity ≥34 Early Treatment of Diabetic Retinopathy Study letters
             (≥20/200) . in the non-study eye.

        Exclusion Criteria:

          -  There are atrophy of the ground pattern involving the fovea, scar or fibrosis, macular
             anterior membrane, rigid exudation under dense fovea, RPE tear in the study eye.

          -  Retinal hemorrhage ≥4 disc area in the study eye.

          -  Dioptric media turbid or the pupil cannot be dilated were significant interference
             with the detection of vision, the evaluation of the anterior segment and fundus in the
             study eye.

          -  Evidence of ocular disease other than exudative AMD in the study eye that may confound
             the outcome of the study (e.g.,Retinal vein occlusion, uveitis, vascular striatum,
             pathological myopia, retinal detachment, macular hole, toxoplasmosis, optic nerve
             disease etc).

          -  History of vitrectomy surgery\macular transposition\glaucoma filtration in the study
             eye.

          -  Photodynamic therapy(PDT), in macular area laser photocoagulation therapy,
             transpermary hyperthermia(TTT), and other operations for AMD within 3 months prior to
             screening visit in the study eye.

          -  History of extraocula surgeryr within 1 months or cataract surgery within 3 months
             prior to screening visit in the study eye.

          -  Aphakia(exclusive of intraocular lens) or rupture of posterior capsule( within1 months
             prior to the YAG laser retrovesiculotomy (after the artificial crystal), was excluded)
             in the study eye.

          -  APD in the study eye or pseudocyst stripping syndrome in either eye.

          -  Intravitrea or Systemicl anti-VEGF injection (ranibizumab, aflibercept, bevacizumab or
             Conbercept etc) in either eye within 3 months prior to screening visit.

          -  Under the conjunctiva,intravitreal or periocular corticosteroid, within 3 months prior
             to screening visit in either eye.

          -  vitreous hemorrhage within 3 months prior to screening Visit in either eye.

          -  Ocular or periocular infection in either eye.

          -  History of glaucoma in either eye.

          -  Visudyne (verteporfin) photodynamic therapy within 1 months prior to screening Visit
             in non-study eye.

          -  Currently in use or may be required to use systemic drugs that cause crystal toxicity
             or retinal toxicity, such as Deferoxamine, chloroquine/ hydroxychloroquine,
             phenothiazine and ethambutol or tamoxifen etc.

          -  Have an allergic reaction or history of allergic reactions to fluorescein sodium and
             indocyanine green, an allergic history to therapeutic or diagnostic protein products,
             an allergic reaction to more than two drugs or non-drug factors, or allergic reactions
             to any monoclonal antibody.

          -  Patients with diabetic retinopathy or the diabetic patient who have glycosylated?
             hemoglobin＞10%.

          -  Patients who have undergone any surgical operation within 1 month prior screening;
             or/and there are unhealed wounds, ulcers, fractures etc.

          -  Systemic infectious diseases with clinical significance requiring oral, intramuscular
             or Patients withintravenous administration.

          -  Myocardial infarction, cerebral infarction and angina pectoris within 6 months prior
             to screening visit.

          -  Patients with active disseminated intravascular coagulation and obvious bleeding
             tendency were screened within 3 months before the screening, or they were treated with
             anticoagulant and antiplatelet therapy other than aspirin/NSAIDs within 14 days before
             the screening.

          -  Patients with Systemic immune disease ,including but not limited to:

        hyperthyroidism, hypothyroidism,vitiligo, dry-syndrome, ankylosing spondylitis, systemic
        nephritis, human immunodeficiency virus (HIV).

          -  Blood pressure control is not ideal or pre-hypertension.

          -  Any uncontrollable clinical problems (Serious mental, nervous, cardiovascular and
             respiratory diseases and malignant tumors).

          -  Abnormal liver and kidney function.

          -  Blood coagulation is abnormal.

          -  Patients with AIDS, syphilis or active hepatitis.

          -  Women are not using effective contraception or in pregnancy,lactation.

          -  Clinical trials of any trial medication or any other experimental or experimental
             therapy may be performed within 3 months prior to screening.

          -  Subject is considered by the investigator, for any reason, to be an unsuitable
             candidate for the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Youxin Chen</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking Union Medical College Hospital, Chinese Academy of Medical Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cailing Gu</last_name>
    <phone>020-22233606</phone>
    <email>clgu@bio-thera.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital, Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Youxin Chen</last_name>
      <phone>010-69151662</phone>
      <email>chenyouxinpumch@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>November 4, 2019</study_first_submitted>
  <study_first_submitted_qc>November 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 5, 2019</study_first_posted>
  <last_update_submitted>November 4, 2019</last_update_submitted>
  <last_update_submitted_qc>November 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

